Acute respiratory distress syndrome (ARDS) is due to diffuse and severe lung inflammation. Despite intensive research, few therapeutics have emerged and treatment is still mostly symptomatic. As lung microbiota seems to be associated with lung inflammation in numerous chronic respiratory diseases, this study aims to analyse the correlation between lung microbiota and mortality.
ARDS is caused by diffuse intense lun inflammation. Its mortality rate is still about 40%. Despite decades of research, few therapeutics have emerged. Treatment is based on the treatment of ARDS cause, if possible and on protective ventilation, curare use and prone position. For more severe cases, nitric monoxide inhalation and extra-corporeal membrane oxygenation can be considered. Nevertheless, no treatment specifically addresses lung inflammation. Lung microbiota has been shown to be associated with lung inflammation in asthma, chronic obstructive disease and cystic fibrosis. Lung microbiota also plays a role in lung immunity. Regarding specifically ARDS, one study correlated lung microbiota with the occurrence of non-infectious ARDS in trauma patients. Thi study therefore aims to analyse the correlation between lung microbiota at admission to ICU for ARDS with mortality.
Study Type
OBSERVATIONAL
Enrollment
70
tracheal aspirate during routine care
Medical intensive care unit, Pellegrin hospital
Bordeaux, New Aquitaine, France
RECRUITINGlung bacteriobiota and ICU mortality
Comparison of lung bacteriobiota alpha diversity between ARDS ICU survivors and non-survivors
Time frame: at admission
lung mycobiota and ICU mortality
Comparison of lung mycobiota alpha diversity between ARDS ICU survivors and non-survivors
Time frame: at admission
lung mycobiota and 1-month mortality
Comparison of lung mycobiota alpha diversity between ARDS 1-month survivors and non-survivors
Time frame: microbiota : at admission, mortality: 1 month after inclusion
lung bacteriobiota and ICU mortality
Analysis of lung bacteriobiota beta diversity between ARDS ICU survivors and non-survivors
Time frame: at admission
lung bacteriobiota and 1-month mortality
Analysis of lung bacteriobiota beta diversity between ARDS 1-month survivors and non-survivors
Time frame: microbiota : at admission, mortality: 1 month after inclusion
lung mycobiota and ICU mortality
Analysis of lung mycobiota beta diversity between ARDS ICU survivors and non-survivors
Time frame: at admission
lung mycobiota and 1-month mortality
Analysis of lung mycobiota beta diversity between ARDS 1-month survivors and non-survivors
Time frame: microbiota : at admission, mortality: 1 month after inclusion
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
bacteria and ICU mortality
Association of bacteria with ARDS ICU mortality by LefSe method
Time frame: at admission
bacteria and 1-month mortality
Association of bacteria with ARDS 1-month mortality by LefSe method
Time frame: microbiota : at admission, mortality: 1 month after inclusion
fungi and ICU mortality
Association of fungi with ARDS ICU mortality by LefSe method
Time frame: at admission
fungi and 1-month mortality
Association of fungi with ARDS 1-month mortality by LefSe method
Time frame: microbiota : at admission, mortality: 1 month after inclusion